UCLA Investigators Lead Study of Novartis’ Ribociclib Significantly Improves Overall Survival for Aggressive Breast Cancer

UCLA Investigators Lead Study of Novartis’ Ribociclib Significantly Improves Overall Survival for Aggressive Breast Cancer

UCLA investigators helped lead a study that found by adding Novartis’ ribociclib, a targeted therapy drug, to standard hormone therapy, they can significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer....

Pin It on Pinterest